

# Development of *In vivo* CAR T using T cell specific Lentivirus

Korea Research Institute of Chemical Technology



ONCOLOGY	Hit
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Cancer/Immune disease
Target	Universal
MoA(Mechanism of Action)	Lentiviral vector specifically targets T cells <i>in vivo</i> and delivers a CAR transgene, enabling the patient's own T cells to be genetically modified inside the body to express tumor-targeting chimeric antigen receptors (CARs). These <i>in vivo</i> CAR-T cells subsequently recognize and eliminate cancer or pathogenic immune cells.
Competitiveness	<ul style="list-style-type: none"> <li>- <i>In vivo</i> CAR-T platform using T cell-specific lentivirus</li> <li>- Eliminates the need for <i>ex vivo</i> manufacturing, reducing cost and complexity</li> <li>- Applicable to a broad range of cancers and immune disorders</li> <li>- Potential for repeat dosing and off-the-shelf scalability</li> <li>- Reduced manufacturing time enables faster clinical application</li> </ul>
Development Stage	Hit
Route of Administration	Intravenous (IV) injection

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*